Alendronate Sodium
Product Images NDC 67296-2054

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 67296-2054). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Alendronate Fig1)

A line graph showing the cumulative incidence of hip fractures over 36 months in a three-year study, comparing placebo and Alendronate Sodium treatment in patients with existing radiographic vertebral fractures. The graph plots cumulative incidence percentage against time in months, with Alendronate Sodium showing a lower incidence than placebo throughout the study period.*

FDA Label Image

Package Label-principal Display Panel (70 mg Blister Carton (4 Unit-of-use))

Alendronate Sodium Tablets, USP 70 mg blister pack packaging label showing a 4-tablet count. Label includes dosage strength, branding by Aurobindo, pharmacist dispensing information, dosage instructions, and medication guide reference. Distributed by Aurobindo Pharma USA, Inc., made in India.*

FDA Label Image

Package Label-principal Display Panel (70 mg (100 Tablets Bottle))

Label for Alendronate Sodium Tablets, USP 70 mg, showing a 100 tablet count. The label includes dosage instructions indicating a once weekly dose and cautions to dispense the Medication Guide separately. Distributed by Aurobindo Pharma USA, Inc., made in India, with storage conditions and additional usage information also displayed.*

FDA Label Image

Figure 2 (Alendronate Fig2)

A bar chart showing the mean percentage increase in bone mineral density (BMD) relative to placebo with Alendronate 10 mg/day over three years in postmenopausal women. The chart compares results from U.S. and multinational osteoporosis treatment studies at three anatomical sites: lumbar spine, femoral neck, and trochanter.*

FDA Label Image

Figure 3 (Alendronate Fig3)

Two line graphs showing the time course effect of Alendronate 10 mg/day versus placebo on lumbar spine bone mineral density (BMD) percent change from baseline in postmenopausal women. The left graph represents a U.S. study, and the right graph a multinational study, both plotting BMD percentage change with Alendronate and placebo over 36 months.*

FDA Label Image

Figure 4 (Alendronate Fig4)

A bar graph comparing the mean percentage change in bone mineral density (BMD) from baseline in postmenopausal women, showing results for Alendronate 5 mg/day versus placebo over 2-year and 3-year osteoporosis prevention studies across lumbar spine, femoral neck, trochanter, and total body sites.*

FDA Label Image

Figure 5 (Alendronate Fig5)

A bar chart showing the increase in bone mineral density (BMD) over one year in glucocorticoid-treated patients taking Alendronate 5 mg/day. The chart compares mean percentage increases at the lumbar spine, femoral neck, and trochanter sites between U.S. and multinational patient groups, with error bars representing standard error.*

FDA Label Image

Figure 6 (Alendronate Fig6)

A line graph showing the effect on serum alkaline phosphatase levels in Paget's disease of bone over 6 months. It compares Alendronate 40 mg/day from multinational and U.S. studies, Etidronate 400 mg/day, and placebo. The y-axis represents mean percent change from baseline, and the x-axis shows time in months, with sample sizes indicated for each group.*

FDA Label Image

Package Label-principal Display Panel (10 mg (30 Tablets Bottle))

Label for Alendronate Sodium Tablets, USP 10 mg by RedPharm Drug featuring NDC 65862-327-30. The label includes dose information stating each tablet contains 13.052 mg alendronate sodium USP equivalent to 10 mg alendronic acid, pharmacist dispensing notes, storage instructions, and distributor details for Aurobindo Pharma USA, Inc. The package contains 30 tablets.*

FDA Label Image

Package Label-principal Display Panel (10 mg Blister Carton 100 (10 x 10) Unit-dose Tablets)

Packaging label for Alendronate Sodium Tablets, USP 10 mg, showing a unit-dose package containing 100 tablets (10 x 10). The label includes dosage information, pharmacist instructions, and storage conditions. The labeler is Aurobindo Pharma USA, Inc., with distribution details and a barcode.*

FDA Label Image

Package Label-principal Display Panel (35 mg Blister Carton (4 Unit-of-use))

Packaging label for Alendronate Sodium Tablets, USP 35 mg, once weekly dosage, containing 4 tablets. The label includes patient and pharmacist instructions, dosage information, and blister pack removal steps. Distributed by Aurobindo Pharma USA, Inc. The label features barcodes, NDC code 65862-328-04, and storage instructions.*

FDA Label Image

Chemical Structure (Alendronate Str)

Chemical structure of Alendronate Sodium showing molecular connectivity, including amino, methylene groups, phosphate groups, sodium ion, and water of hydration.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.